EHAB · Enhabit, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $264.80M | - | $263.60M | $266.10M | $259.90M | - | $253.60M | $260.60M | $262.40M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $96.70M | - | $105.50M | $108.20M | $107.50M | - | $103.80M | $110.00M | $107.50M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $4.60M | - | $5.50M | $5.70M | $6.30M | - | $8.20M | $7.60M | $7.80M | - |
| Operating Income | $29.30M | - | $16.80M | $16.70M | $15.90M | - | ($98.00M) | $11.20M | $12.90M | - |
| Interest Expense | - | - | - | - | - | - | - | - | $11.10M | - |
| Income Tax | $3.10M | - | ($3.20M) | $2.30M | $7.40M | - | $700.0K | ($100.0K) | $900.0K | - |
| Net Income | $19.20M | - | $11.10M | $5.20M | $17.80M | - | ($110.20M) | ($200.0K) | $200.0K | - |
| EPS - Basic | $0.37 | - | $0.22 | $0.10 | $0.35 | - | ($2.20) | $0.00 | $0.01 | - |
| EPS - Diluted | $0.36 | - | $0.22 | $0.10 | $0.35 | - | ($2.20) | $0.00 | $0.01 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.00M | $43.60M | $56.90M | $37.10M | $39.50M | $28.40M | $45.70M | $28.50M | $36.50M | $27.40M |
| Accounts Receivable | $154.40M | $144.00M | $148.70M | $158.50M | $160.90M | $149.20M | $150.90M | $166.00M | $174.30M | $164.70M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.60M | $9.20M | $7.20M | $11.50M | $8.00M | $6.70M | $9.90M | $8.50M | $9.00M | $7.60M |
| Current Assets | $219.20M | $205.60M | $213.70M | $205.50M | $211.30M | $192.70M | $208.20M | $206.80M | $226.10M | $210.10M |
| Total Assets | $1.18B | $1.17B | $1.23B | $1.23B | $1.24B | $1.23B | $1.30B | $1.42B | $1.45B | $1.43B |
| Current Liabilities | $140.20M | $126.30M | $135.50M | $130.90M | $141.50M | $126.20M | $142.90M | $140.10M | $150.50M | $137.70M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $595.00M | $603.00M | $631.00M | $642.50M | $662.60M | $672.10M | $706.40M | $713.60M | $740.20M | $731.90M |
| Stockholders' Equity | $553.50M | $534.00M | $566.80M | $552.40M | $543.20M | $523.50M | $566.10M | $674.30M | $672.30M | $669.70M |
| Retained Earnings | - | $93.70M | - | - | - | $98.30M | - | - | - | $254.50M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $35.20M | - | - | - | $17.90M | - | - | - | $17.30M | - |
| Investing Cash Flow | ($2.60M) | - | - | - | $20.80M | - | - | - | ($1.10M) | - |
| Financing Cash Flow | ($26.60M) | - | - | - | ($28.20M) | - | - | - | ($6.60M) | - |
| CapEx | $2.50M | - | - | - | $300.0K | - | - | - | $1.80M | - |
| Free Cash Flow | $32.70M | - | - | - | $17.60M | - | - | - | $15.50M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 11.1% | - | 6.4% | 6.3% | 6.1% | - | -38.6% | 4.3% | 4.9% | - |
| EBITDA margin | 12.8% | - | 8.5% | 8.4% | 8.5% | - | -35.4% | 7.2% | 7.9% | - |
| Net margin | 7.3% | - | 4.2% | 2.0% | 6.8% | - | -43.5% | -0.1% | 0.1% | - |
| Free cash flow margin | 12.3% | - | - | - | 6.8% | - | - | - | 5.9% | - |
| FCF / Net income | 1.70 | - | - | - | 0.99 | - | - | - | 77.50 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 36.5% | - | 40.0% | 40.7% | 41.4% | - | 40.9% | 42.2% | 41.0% | - |
| Effective tax rate | 13.9% | - | -40.5% | 30.7% | 29.4% | - | - | - | 81.8% | - |
| Return on assets | 1.6% | - | 0.9% | 0.4% | 1.4% | - | -8.4% | -0.0% | 0.0% | - |
| Return on equity | 3.5% | - | 2.0% | 0.9% | 3.3% | - | -19.5% | -0.0% | 0.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.56 | 1.63 | 1.58 | 1.57 | 1.49 | 1.53 | 1.46 | 1.48 | 1.50 | 1.53 |
| Quick ratio | 1.56 | 1.63 | 1.58 | 1.57 | 1.49 | 1.53 | 1.46 | 1.48 | 1.50 | 1.53 |
| Cash ratio | 0.36 | 0.35 | 0.42 | 0.28 | 0.28 | 0.23 | 0.32 | 0.20 | 0.24 | 0.20 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | 1.2x | - |
| Equity multiplier | 2.13 | 2.19 | 2.17 | 2.22 | 2.28 | 2.34 | 2.30 | 2.10 | 2.15 | 2.14 |
| Liabilities / Assets | 0.50 | 0.52 | 0.51 | 0.52 | 0.54 | 0.55 | 0.54 | 0.50 | 0.51 | 0.51 |
| Efficiency | ||||||||||
| Asset turnover | 0.22 | - | 0.21 | 0.22 | 0.21 | - | 0.19 | 0.18 | 0.18 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 213d | - | 206d | 217d | 226d | - | 217d | 233d | 242d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 39.1x | - | 36.4x | 96.4x | 25.1x | - | - | - | 1165.0x | - |
| P / B | 1.3x | - | 0.7x | 0.9x | 0.8x | - | 0.7x | 0.7x | 0.9x | - |
| P / S | 2.8x | - | 1.6x | 1.9x | 1.7x | - | 1.6x | 1.7x | 2.2x | - |
| EV / EBITDA | 20.5x | - | 15.8x | 20.5x | 18.3x | - | - | 22.3x | 26.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1.9% | - | 3.9% | 2.1% | -1.0% | - | -1.8% | -0.6% | -1.0% | - |
| Revenue CAGR (3y) | -0.0% | - | -1.3% | -0.2% | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 84.3% | - | - | 49.1% | 23.3% | - | - | - | -63.6% | - |
| Net income growth (YoY) | 7.9% | - | - | - | 8800.0% | - | -4491.7% | 99.7% | -92.6% | - |
| EPS growth (YoY) | 2.9% | - | - | - | 3400.0% | - | -4300.0% | - | -80.0% | - |
| EPS CAGR (3y) | 93.1% | - | -20.6% | -37.5% | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 85.8% | - | - | - | 13.5% | - | - | - | -62.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1.9% | 2.0% | 0.1% | -18.1% | -19.2% | -21.8% | -16.3% | -0.1% | -9.7% | -9.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$697.00M totalHome Health Segment$455.20M · 65.3%
Hospice Segment$241.80M · 34.7%
Product / service
$813.80M totalMedicare$455.20M · 55.9%
Non Medicare$350.80M · 43.1%
Other Service Line$7.80M · 1.0%
Peer comparison
Same SIC group: Services-Home Health Care Services
Comparing Enhabit against the 5 most active filers in the same SIC group.